YAP1 and cancer: Since UHRF1 is highly expressed in cancer, while YAP signalling is known to trigger cancer initiation and growth of solid tumours, our study emphasises the possible benefits given by small compounds interventions targeting PIP4K as treatment for specific YAP-addicted cancer types.